About Rhythm Pharmaceuticals

Transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor pathway diseases

hero image
Individuals with variants in genes in the melanocortin-4 receptor (MC4R) pathway or injury to the hypothalamic region may impair pathway activation which can lead to hyperphagia (pathological, insatiable hunger) and severe obesity

Our Pipeline

Rhythm has developed setmelanotide, a melanocortin-4 receptor (MC4R) agonist that may restore impaired MC4R pathway function caused by genetic variants that occur upstream of the receptor.1

Rare Genetic Diseases of Obesity


Hypothalamic Obesity



  1. Collet TH, et al. Mol Metab. 2017;6(10):1321-1329.

The information contained on this site is intended for US health care professionals only